Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 105

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Clonal hematopoiesis in cardiovascular disease and therapeutic implications

Tall, Alan R., Fuster, Jose J.·2022·Nature Cardiovascular Research
DOI 10.1038/s44161-021-00015-3PMC PMC9631799
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s44161-021-00015-3

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 84

  1. Marnell, C. S., Bick, A. & Natarajan, P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J. Mol. Cellular Cardiol. 161, 98–105 (2021). · DOI
  2. Steensma, D. P. et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 126, 9–16 (2015). · DOI · Paper page
  3. Yu, B. et al. Supplemental association of clonal hematopoiesis with incident heart failure. J. Am. Coll. Cardiol. 78, 42–52 (2021). In a meta-analysis of different studies some, but not all, CHIP variants were found to be associated with an increased incidence of heart failure. · DOI · Paper page
  4. Pascual-Figal, D. A. et al. Clonal hematopoiesis and risk of progression of heart failure with reduced left ventricular ejection fraction. J. Am. Coll. Cardiol. 77, 1747–1759 (2021). · DOI · Paper page
  5. Dorsheimer, L. et al. Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA cardiology 4, 25–33 (2019). · DOI · Paper page
  6. Mas-Peiro, S. et al. Clonal haematopoiesis in patients with degenerative aortic valve stenosis undergoing transcatheter aortic valve implantation. Eur. Heart J. 41, 933–939 (2020). · DOI · Paper page
  7. Jaiswal, S. & Libby, P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat. Rev. Cardiol. 17, 137–144 (2020). · DOI · Paper page
  8. Yura, Y., Sano, S. & Walsh, K. Clonal hematopoiesis: a new step linking inflammation to heart failure. JACC Basic Transl. Sci. 5, 196–207 (2020). · DOI
  9. Libby, P. The changing landscape of atherosclerosis. Nature 592, 524–533 (2021). · DOI · Paper page
  10. Zekavat, S. M. et al. TP53-mediated clonal hematopoiesis confers increased risk for incident peripheral artery disease. Preprint at medRxiv https://doi.org/10.1101/2021.08.22.21262430 (2021). · DOI
  11. Hannum, G. et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Molecular cell 49, 359–367 (2013). · DOI · Paper page
  12. Levine, M. E. et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging 10, 573–591 (2018). · DOI · Paper page
  13. Robertson, N. A. et al. Age-related clonal haemopoiesis is associated with increased epigenetic age. Curr. Biol. 29, R786–R787 (2019). · DOI · Paper page
  14. Nachun, D. et al. Clonal hematopoiesis associated with epigenetic aging and clinical outcomes. Aging Cell 20, e13366 (2021). · DOI
  15. Busque, L. et al. Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nat. Genet. 44, 1179–1181 (2012). · DOI · Paper page
  16. Ko, M. et al. Ten-eleven-translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice. PNAS 108, 14566–14571 (2011). · DOI · Paper page
  17. Liu, D. J. et al. Exome-wide association study of plasma lipids in >300,000 individuals. Nat. Genet. 49, 1758–1766 (2017). · DOI · Paper page
  18. Cordua, S. et al. Prevalence and phenotypes of JAK2V617F and calreticulin mutations in a Danish general population. Blood 134, 469–479 (2019). · DOI
  19. Yokokawa, T. et al. Crucial role of hematopoietic JAK2V617F in the development of aortic aneurysms. Haematologica 106, 1910–1922 (2021). · DOI
  20. Luque Paz, D., Ashcroft, P. & Skoda, R. C. Myeloproliferative neoplasms: the long wait for JAK2-mutant clone expansion. Cell Stem Cell 28, 359–361 (2021). · DOI
  21. Wang, W. et al. Macrophage inflammation, erythrophagocytosis, and accelerated atherosclerosis in Jak2 (V617F) mice. Circ. Res. 123, e35–e47 (2018). · DOI · Paper page
  22. Fidler, T. P. et al. The AIM2 inflammasome exacerbates atherosclerosis in clonal haematopoiesis. Nature 592, 296–301 (2021). These authors implicate AIM2 inflammasome activation in the accelerated atherosclerosis of Jak2VF clonal hematopoiesis mice and show beneficial effects of treatment with IL-1β antibodies. · DOI · Paper page
  23. Edelmann, B. et al. JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation. J. Clin. Invest. 128, 4359–4371 (2018). · DOI · Paper page
  24. Shimada, K. et al. Oxidized mitochondrial DNA activates the NLRP3 inflammasome during apoptosis. Immunity 36, 401–414 (2012). · DOI · Paper page
  25. Hu, B. et al. The DNA-sensing AIM2 inflammasome controls radiation-induced cell death and tissue injury. Science 354, 765–768 (2016). · DOI
  26. Nilsson, J. & Hansson, G. K. The changing face of atherosclerotic plaque inflammation. J. Intern. Med. 278, 430–432 (2015). · DOI
  27. Rauch, P. J. et al. Loss-of-function mutations in Dnmt3a and Tet2 lead to accelerated atherosclerosis and convergent macrophage phenotypes in mice. Blood 132, 745 (2018). · DOI
  28. Sano, S. et al. CRISPR-mediated gene editing to assess the roles of Tet2 and Dnmt3a in clonal hematopoiesis and cardiovascular disease. Circ. Res. 123, 335–341 (2018). · DOI · Paper page
  29. Lim, J. Y. et al. DNMT3A haploinsufficiency causes dichotomous DNA methylation defects at enhancers in mature human immune cells. J. Exp. Med. 218, e20202733 (2021) · DOI
  30. Kim, P. G. et al. Dnmt3a-mutated clonal hematopoiesis promotes osteoporosis. J. Exp. Med. 218, e20211872 (2021). · DOI · Paper page
  31. Falanga, A. & Marchetti, M. Thrombotic disease in the myeloproliferative neoplasms. Hematology/the Education Program of the American Society of Hematology. American Society of Hematology. Education Program 2012, 571–581 (2012).
  32. Zhao, B. et al. Loss of pleckstrin-2 reverts lethality and vascular occlusions in JAK2V617F-positive myeloproliferative neoplasms. J. Clin. Invest. 128, 125–140 (2018). · DOI
  33. Gudbjartsson, D. F. et al. Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction. Nat. Genet. 41, 342–347 (2009). · DOI · Paper page
  34. Wang, W. et al. LNK/SH2B3 loss of function promotes atherosclerosis and thrombosis. Circ. Res. 119, e91–e103 (2016). · DOI
  35. Dou, H. et al. Oxidized phospholipids promote NETosis and arterial thrombosis in LNK(SH2B3) deficiency. Circulation 144, 1940–1954 (2021). · DOI
  36. Cremer, S. et al. Multiple somatic mutations for clonal hematopoiesis are associated with increased mortality in patients with chronic heart failure. Circ. Genom. Precis. Med. 13, e003003 (2020). · DOI
  37. Palomo, L. et al. Prevalence and characteristics of clonal hematopoiesis in heart failure. Rev. Esp. Cardiol. 74, 996–999 (2021). · DOI
  38. Assmus, B. et al. Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations. Eur. Heart J. 42, 257–265 (2021). · DOI
  39. Kiefer, K. C. et al. Full spectrum of clonal haematopoiesis-driver mutations in chronic heart failure and their associations with mortality. ESC Heart Fail 8, 1873–1884 (2021). · DOI
  40. Adamo, L., Rocha-Resende, C., Prabhu, S. D. & Mann, D. L. Reappraising the role of inflammation in heart failure. Nat. Rev. Cardiol. 17, 269–285 (2020). · DOI
  41. Abplanalp, W. T. et al. Clonal hematopoiesis-driver DNMT3A mutations alter immune cells in heart failure. Circ. Res. 128, 216–228 (2021). · DOI
  42. Sano, S. et al. Tet2-mediated clonal hematopoiesis accelerates heart failure through a mechanism involving the IL-1β/NLRP3 inflammasome. J. Am. Coll. Cardiol. 71, 875–886 (2018). · DOI · Paper page
  43. Sano, S. et al. JAK2V617F-mediated clonal hematopoiesis accelerates pathological remodeling in murine heart failure. JACC Basic Transl. Sci. 4, 684–697 (2019). · DOI · Paper page
  44. Bolton, K. L. et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat. Genet. 52, 1219–1226 (2020). · DOI · Paper page
  45. Sano, S. et al. TP53-mediated therapy-related clonal hematopoiesis contributes to doxorubicin-induced cardiomyopathy by augmenting a neutrophil-mediated cytotoxic response. JCI Insight 6, e146076 (2021). · DOI
  46. Yura, Y. et al. The cancer therapy-related clonal hematopoiesis driver gene Ppm1d promotes inflammation and non-ischemic heart failure in mice. Circ. Res. 129, 684–698 (2021). · DOI · Paper page
  47. Yvan-Charvet, L. et al. ATP-binding cassette transporters and HDL suppress hematopoietic stem cell proliferation. Science 328, 1689–1693 (2010). · DOI
  48. Harslof, M., Pedersen, K. M., Nordestgaard, B. G. & Afzal, S. Low high-density lipoprotein cholesterol and high white blood cell counts: a mendelian randomization study. Arter. Thromb. Vasc. Biol. 41, 976–987 (2021). · DOI
  49. Adamstein, N. H. et al. The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. Eur. Heart J. 42, 896–903 (2021). · DOI
  50. Bonnefond, A. et al. Association between large detectable clonal mosaicism and type 2 diabetes with vascular complications. Nat. Genet. 45, 1040–1043 (2013). · DOI · Paper page
  51. Fuster, J. J. et al. TET2-loss-of-function-driven clonal hematopoiesis exacerbates experimental insulin resistance in aging and obesity. Cell Rep. 33, 108326 (2020). · DOI · Paper page
  52. Honigberg, M. C. et al. Premature menopause, clonal hematopoiesis, and coronary artery disease in postmenopausal women. Circulation 143, 410–423 (2021). · DOI · Paper page
  53. Ruth, K. S. et al. Genetic insights into biological mechanisms governing human ovarian ageing. Nature 596, 393–397 (2021). · DOI
  54. Lusis, A. J. A vicious cycle in atherosclerosis. Cell 184, 1139–1141 (2021). · DOI
  55. Sanchez-Cabo, F. & Fuster, J. J. Clonal haematopoiesis and atherosclerosis: a chicken or egg question? Nat. Rev. Cardiol. 18, 463–464 (2021).
  56. Ogawa, M. Differentiation and proliferation of hematopoietic stem cells. Blood 81, 2844–2853 (1993). · DOI
  57. Bick, A. G. et al. Genetic IL-6 signaling deficiency attenuates cardiovascular risk in clonal hematopoiesis. Circulation https://doi.org/10.1161/CIRCULATIONAHA.119.044362 (2019). In people with TET2 or DNMT3A clonal hematopoiesis the increased risk of atherosclerotic CVD was reversed if they also carried a genetic variant in the IL-6 receptor that reduced its function. · DOI · Paper page
  58. Heron, M. Deaths: leading causes for 2015. Natl. Vital Stat. Rep. 66, 1–76 (2017).
  59. Vallejo-Vaz, A. J. et al. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. Circulation 138, 770–781 (2018). · DOI · Paper page
  60. Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017). · DOI · Paper page
  61. Martinon, F., Petrilli, V., Mayor, A., Tardivel, A. & Tschopp, J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 440, 237–241 (2006). · DOI · Paper page
  62. Misawa, T. et al. Microtubule-driven spatial arrangement of mitochondria promotes activation of the NLRP3 inflammasome. Nat. Immunol. 14, 454–460 (2013). · DOI
  63. Imazio, M. & Nidorf, M. Colchicine and the heart. Eur. Heart J. 42, 2745–2760 (2021). · DOI
  64. Newby, L. K. Inflammation as a treatment target after acute myocardial infarction. N.Engl. J. Med. 381, 2562–2563 (2019). · DOI
  65. Ren, G. M. et al. Pharmacological targeting of NLRP3 deubiquitination for treatment of NLRP3-associated inflammatory diseases. Sci. Immunol. 6, eabe2933 (2021). · DOI
  66. Mangan, M. S. J. et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat. Rev. Drug Discovery 17, 588–606 (2018). · DOI · Paper page
  67. Paulin, N. et al. Double-Strand DNA sensing Aim2 inflammasome regulates atherosclerotic plaque vulnerability. Circulation 138, 321–323 (2018). · DOI
  68. Dinarello, C. A., Novick, D., Kim, S. & Kaplanski, G. Interleukin-18 and IL-18 binding protein. Front. Immunol. 4, 289 (2013). · DOI · Paper page
  69. Whitman, S. C., Ravisankar, P. & Daugherty, A. Interleukin-18 enhances atherosclerosis in apolipoprotein E−/− mice through release of interferon-gamma. Circ. Res. 90, E34–E38 (2002). · DOI
  70. Wang, J. et al. Interleukin 18 function in atherosclerosis is mediated by the interleukin 18 receptor and the Na-Cl co-transporter. Nat. Med. 21, 820–826 (2015). · DOI
  71. Gupta, S. et al. IFN-γ potentiates atherosclerosis in ApoE knock-out mice. J. Clin. Invest. 99, 2752–2761 (1997). · DOI
  72. Ridker, P. M. & Rane, M. Interleukin-6 signaling and anti-interleukin-6 therapeutics in cardiovascular Disease. Circ. Res. 128, 1728–1746 (2021). · DOI · Paper page
  73. Galicia, J. C. et al. Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun. 5, 513–516 (2004). · DOI
  74. Huber, S. A., Sakkinen, P., Conze, D., Hardin, N. & Tracy, R. Interleukin-6 exacerbates early atherosclerosis in mice. Arter. Thromb. Vasc. Biol. 19, 2364–2367 (1999). · DOI · Paper page
  75. Schuett, H. et al. Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice. Arter. Thromb. Vasc. Biol. 32, 281–290 (2012). · DOI
  76. Schieffer, B. et al. Impact of interleukin-6 on plaque development and morphology in experimental atherosclerosis. Circulation 110, 3493–3500 (2004). · DOI · Paper page
  77. Pierini, F. S. et al. Effect of tocilizumab on LDL and HDL characteristics in patients with rheumatoid arthritis. An observational study. Rheumatol. Ther. 8, 803–815 (2021). · DOI
  78. Ridker, P. M. et al. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet 397, 2060–2069 (2021). · DOI
  79. Cimmino, L. et al. Restoration of TET2 function blocks aberrant self-renewal and leukemia progression. Cell 170, 1079–1095(2017). · DOI · Paper page
  80. Tang, Y. et al. Inhibition of JAK2 suppresses myelopoiesis and atherosclerosis in Apoe−/− mice. Cardiovasc. Drugs Ther. 34, 145–152 (2020). · DOI
  81. Rao, T. N. et al. JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms. Blood 134, 1832–1846 (2019). · DOI
  82. Rocca, B. et al. A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. Blood 136, 171–182 (2020). · DOI
  83. Bersenev, A. et al. Lnk constrains myeloproliferative diseases in mice. J. Clin. Invest. 120, 2058–2069 (2010). · DOI
  84. Lv, K. et al. CBL family E3 ubiquitin ligases control JAK2 ubiquitination and stability in hematopoietic stem cells and myeloid malignancies. Genes Dev. 31, 1007–1023 (2017). · DOI

Cited by

Metadata

Authors
Tall, A. R., & Fuster, J. J.
Venue
Nature Cardiovascular Research
Publisher
Springer Science and Business Media LLC
Published
2022-02-07
Volume
1
Issue
2
Pages
116-124
ISSN
2731-0590
DOI
10.1038/s44161-021-00015-3
PMC
PMC9631799
Cited by
105
References
22
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review